Su GH - Search Results

1

Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer.

Su GH, Xiao Y, Jiang L, Zheng RC, Wang H, Chen Y, Gu YJ, You C, Shao ZM. Su GH, et al. J Transl Med. 2022 Oct 15;20(1):471. doi: 10.1186/s12967-022-03688-x. J Transl Med. 2022. PMID: 36243806 Free PMC article.

2

Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence.

Xu Y, Su GH, Ma D, Xiao Y, Shao ZM, Jiang YZ. Xu Y, et al. Among authors: su gh. Signal Transduct Target Ther. 2021 Aug 20;6(1):312. doi: 10.1038/s41392-021-00729-7. Signal Transduct Target Ther. 2021. PMID: 34417437 Free PMC article. Review.

3

A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer.

Peng W, Lin C, Jing S, Su G, Jin X, Di G, Shao Z. Peng W, et al. Front Oncol. 2021 Sep 16;11:746763. doi: 10.3389/fonc.2021.746763. eCollection 2021. Front Oncol. 2021. PMID: 34604089 Free PMC article.

4

ASO Author Reflections: Deeper Insight into Therapeutic Implications and Non-invasive Detection of Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Results from a Multi-omics Cohort Study.

Su GH, Jiang L, Xiao Y, Zheng RC, Wang H, Jiang YZ, Peng WJ, Shao ZM, Gu YJ, You C. Su GH, et al. Ann Surg Oncol. 2022 Oct;29(11):7176-7177. doi: 10.1245/s10434-022-11960-z. Epub 2022 May 29. Ann Surg Oncol. 2022. PMID: 35644861 No abstract available.

5

A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer.

Su GH, Jiang L, Xiao Y, Zheng RC, Wang H, Jiang YZ, Peng WJ, Shao ZM, Gu YJ, You C. Su GH, et al. Ann Surg Oncol. 2022 Oct;29(11):7165-7175. doi: 10.1245/s10434-022-11958-7. Epub 2022 Jun 16. Ann Surg Oncol. 2022. PMID: 35711018

6

[No title available]

[No authors listed] [No authors listed] PMID: 35838902

7

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer.

Jiang L, You C, Xiao Y, Wang H, Su GH, Xia BQ, Zheng RC, Zhang DD, Jiang YZ, Gu YJ, Shao ZM. Jiang L, et al. Among authors: su gh. Cell Rep Med. 2022 Jul 19;3(7):100694. doi: 10.1016/j.xcrm.2022.100694. Cell Rep Med. 2022. PMID: 35858585 Free PMC article.

8

Uncovering the molecular subtypes of triple-negative breast cancer with a noninvasive radiomic methodology.

Su GH, Xiao Y, Jiang YZ, Shao ZM. Su GH, et al. Cell Rep Med. 2022 Dec 20;3(12):100808. doi: 10.1016/j.xcrm.2022.100808. Cell Rep Med. 2022. PMID: 36543098 Free PMC article.

9

Prediction of clinicopathological features, multi-omics events and prognosis based on digital pathology and deep learning in HR⁺/HER2^- breast cancer.

Hu J, Lv H, Zhao S, Lin CJ, Su GH, Shao ZM. Hu J, et al. Among authors: su gh. J Thorac Dis. 2023 May 30;15(5):2528-2543. doi: 10.21037/jtd-23-445. Epub 2023 May 23. J Thorac Dis. 2023. PMID: 37324098 Free PMC article.

10

Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets.

Su GH, Xiao Y, You C, Zheng RC, Zhao S, Sun SY, Zhou JY, Lin LY, Wang H, Shao ZM, Gu YJ, Jiang YZ. Su GH, et al. Sci Adv. 2023 Oct 6;9(40):eadf0837. doi: 10.1126/sciadv.adf0837. Epub 2023 Oct 6. Sci Adv. 2023. PMID: 37801493 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page